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ABSTRACT 
Objective: We previously found that total saponins, purified from the caudexes and leaves of Panax notoginseng (SCLPN), had antidepressant effects. In 
the present study, we investigated saponin monomers of SCLPN that may be the main constituents that contribute to the antidepressant effects of SCLPN.  
Methods: Three effective fractions of SCLPN, purified using a macroporous resin method, at doses of 50 and 100 mg/kg were tested in four different 
animal models of stress, including the learned helplessness test, tail suspension test, forced swim test, open field test, and reserpine-induced syndrome 
model. Using the same models of stress and the same doses, we then evaluated the antidepressant effects of four main and representative saponin 
monomers (ginsenosides Rd, Rb1 and Rg1 and notoginsenoside R1) in different effective fractions. We also examined the effects of Rd and Rb3 on 
monoamine neurotransmitter levels. To investigate the biotransformation of Rb1 and Rb3 orally administered in mice, Rb1 and Rb3 metabolites in blood 
and brain were determined by high-performance liquid chromatography. 
Results: Effective fraction A and C exerted greater antidepressant effects than fraction B in the behavioral tests and reserpine-induced syndrome model. 
Among the four saponin monomers, Rd had the strongest antidepressant effects, which improved depressive-like behavior in all four animal models of 
depression. We then found that Rb3 (50 and 100 mg/kg) and Rd (100 mg/kg) increased the levels of 5-hydroxytryptamine, dopamine, and 
norepinephrine, whereas 50 mg/kg Rd had no effect on the levels of these three neurotransmitters. Ginsenoside Rh2, C-K, and 20 (S)-protopanaxadiol 
saponins were detected in blood samples from mice that received Rb1 and Rb3, and protopanaxadiol saponins were found in the brain.  
Conclusion: The present results indicate that protopanaxadiol saponins in SCLPN have potential antidepressant-like effects. 
Keywords: Effective fraction, SCLPN, Ginsengnoside Rb3, Ginsengnoside Rd, Ginsengnoside Rb1, Ginsengnoside Rg1, Notoginsenoside R1, 
Antidepressant, Animal model, Macroporous resin. 
 
INTRODUCTION 
Depression has become a serious and deliberating health problem 
worldwide [1]. For example, a recent survey conducted from 2006 to 
2008 indicated that 9.0% of 235,067 American adults met the criteria 
for current depression, including 3.4% who met the criteria for major 
depression [2]. The symptoms of depression include sadness, loss of 
interest or pleasure in usual activities, changes in weight and appetite, 
sleeplessness, energy loss, hopelessness, and even suicidal tendencies 
[3]. Although no conclusive theory exists to explain the pathogenesis of 
depression [4], disturbances in the function of monoaminergic 
neurotransmitters including 5-hydroxytryptamine (5-HT), 
norepinephrine (NE), and dopamine (DA) [5-7], are commonly 
accepted as being associated with the pathogenesis of depression. 
With regard to pharmacological treatments for depression, selective 
serotonin reuptake inhibitors (SSRIs) are the most common, including 
fluoxetine and paroxetine. Serotonin norepinephrine reuptake 
inhibitors (SNRIs) are also widely available, including desvenlafaxine, 
venlafaxine, and duloxetine. Additionally, tricyclic antidepressants 
(TCAs) and monoamine oxidase inhibitors (MAOIs) have been used in 
the past but now have been mostly discarded [8-10]. These 
medications have some efficacy but tend to be associated with such 
side effects as sedation, sleep disturbances, apathy, fatigue, sexual 
dysfunction, and cognitive impairment [11]. Therefore, more effective 
and better-tolerated antidepressants are still needed. Increasingly 
more herbal medicines have been used as alternative remedies for 
depression, such as St. John's wort (Hypericum perforatum) [12, 13], 
Curcuma longa [14], Asparagus racemosus [15], and Salviasclarea [16]. 
Many of these are available as over-the-counter psychotropic herbal 
medicines. They are fairly safe and present fewer side effects 
compared with conventional pharmacotherapies [17]. Thus, herbal 
remedies may be prospective alternatives for the treatment of 
depression. 
Several medicinal plants of the Panax genus, including Panax ginseng C. 
A. Mey. (ginseng), Panax quinquefolius L. (American ginseng), and 
Panax notoginseng (Burk.) F. H. Chen (notoginseng), are renowned and 
widely used in China. Asian ginseng and American ginseng are mainly 
used as tonics and stimulants, whereas notoginseng is used to 
eliminate blood stasis and arrest bleeding [18]. Modern 
pharmacological research on notoginseng has indicated that various 
therapeutic effects on different body systems [19, 20]. P. notoginseng 
contains dozens of drammarane triterpene saponins, which can be 
classified into two groups two groups— 20(S)-protopanaxatriol 
saponins (PTSs) and 20(S)-protopanaxadiol saponins (PDSs)—
according to different aglycons [21]. The root of Panax notoginseng 
contains nearly equal amounts of PTSs and PDSs, but the leaves and 
flowers mostly include protopanaxadiol (ppd)-type saponins [22]. 
Numerous ginsenosides and notoginsenosides have been isolated from 
the total saponins of the caudexes and leaves of Panax notoginseng 
(SCLPN). Among these constituents, ginsenosides Rb3, Rb1, and Rc and 
notoginsenoside Fc were found in high concentrations in SCLPN, which 
all belonged to PDSs [23, 24]. Several studies have reported the effects 
of SCLPN for the treatment of anxiety, insomnia, and neurasthenia 
neurosis [25, 26]. Recently, studies in our laboratory demonstrated 
that SCLPN possessed potential antidepressant effects [27].  
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Specifically, ginsenoside Rb3, which is found in high amounts in SCLPN, 
has been shown to have antidepressant-like effects in several 
behavioral tests in mice [28]. Thus, we further purified SCLPN using a 
macroporous resin method and investigated the possible 
antidepressant-like effects of three effective fractions in rodent models 
of depression. To determine which types of saponin monomers in 
SCLPN are the main components that contribute to its anti 
depressant effects, we evaluated four main and representative saponin 
monomers (ginsenosides Rd, Rb1, and Rg1 and notoginsenoside R1) 
and ginsenoside Rb3 in different effective fractions. The metabolites of 
Rb1 and Rb3 in mouse blood and brain were detected to better 
understand the differences in the effects of these monomers. 
MATERIALS AND METHODS 
Animals  
KM mice (Experimental Animal Center of Zhongshan School of 
Medicine, Guangdong, China), weighing 18-22 g at the beginning of the 
study, were group-housed under standard laboratory conditions (24 ± 
2 °C; 12 h/12 h light/dark cycle) with standard food and water 
available ad libitum. All of the experiments were conducted in 
compliance with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals (NIH Publication no. 85-23, revised 
1985) and the Animal Welfare Committee of Sun Yat-Sen University. 
All efforts were made to minimize the number of animals used and 
their suffering. 
Drugs and chemicals 
Paroxetine (Smith Kline, Tianjin, China), maprotiline and anafranil 
(Novartis, Beijing, China), and fluoxetine (Patheon, Bourgoin-Jallieu, 
France) were used as positive control drugs. 5-hydroxytryptophan (5-
HTP) (Adobe Fournier Biological Technology, Nanjing, China) and 
clonidine (Advanced Technology and Industry Company, Hong Kong, 
China) were separately dissolved in sterilized physiological saline to 
form 10.0 mg/ml 5-HTP solutions and 5.0 mg/ml clonidine solutions. 
L-DOPA (Adobe Fournier Biological Technology, Nanjing, China) was 
first dissolved in hydrochloric acid solution (1 M), to which ascorbic 
acid (0.2 mg/ml) and NaH2PO3 (30 mg/ml) were successively added to 
form 10.0 mg/ml L-DOPA solutions. NaCl, ascorbic acid, and NaH2PO3 
were all analytical grade and purchased from Guangzhou Chemical 
Reagent Factory (Guangzhou, China). 
Effective fractions purified with macroporous resins from total 
saponins and saponin monomers  
Effective fractions from the total saponins were extracted and purified 
using macroporous resins. D101 macroporous resins were 
sequentially pretreated with 95% ethanol, 1 M HCl solution, and 1 M 
NaOH solution to remove the resin residues and porogenic agents 
trapped inside the pores during the synthesis process. Macroporous 
resins were then thoroughly washed with distilled water. Total 
saponins (5 g) from the caudexes and leaves of Panax notoginseng 
(Guangdong Medi-World Pharmaceutical Co. Ltd. Foshan, China) were 
dissolved with 50 ml distilled water and filtered. The filtrate was then 
absorbed on a glass column (60 × 2 cm) that was wet-packed with 
D101 macroporous resin. The column was eluted with a gradient 
elution of 50%, 60%, 70%, 80%, and 90% ethanol at an optimized flow 
rate of 3 BV/h. After the resulting elution was respectively 
concentrated in a rotary evaporator under reduced pressure and 
further dried under vacuum, five fractions were obtained. Their 
chemical components were determined by high-performance liquid 
chromatography (HPLC). Among these, the fractions that were 
obtained with the 50% and 60% ethanol elutions showed nearly equal 
components, similar to the fractions obtained with the 80%and 90% 
ethanol elutions. The 60%, 70%, and 80% elution fractions, referred to 
as fractions A, B, and C, respectively, was chosen for further evaluation 
of their antidepressant effects, and SCLPN was referred to as total 
saponins D.  
Ginsenosides Rd, Rb1, and Rg1 and notoginsenoside R1 (purity > 98%; 
Plant Pharmaceutical Company, Yunnan, China) and ginsenoside Rb3 
(purity > 90%; Fengshanjian, Kunming, China) were purified by HPLC. 
The structural formulas of the main ginsenosides Rd, Rb1, Rb3, Rg1, 
and R1 are shown in Fig.1. Fractions A, B, and C, total saponins D, and 
all of dosages are expressed as milligrams per kilogram body weight. 
 
 
Compounds R1 R2 R3 
GinsenosideRd -Oglc（2→1）glc -OH -Oglc 
GinsenosideRb1 -Oglc（2→1）glc -OH -Oglc（6→1）glc 
GinsenosideRb3 -Oglc（2→1）glc -OH -Oglc（6→1）xyl 
GinsenosideRg1 -OH -Oglc -Oglc 
NotoginsenosideR1 -OH -Oglc（2→1）xyl -Oglc 
Fig. 1: It shows chemical structure of Panax notoginsenoside R1 and ginsenoside Rg1, Rd, Rb1, and Rb3. 
 
Open field test  
Psychostimulants may show antidepressant-like effects in the forced 
swim test (FST), but they are clinically ineffective as antidepressants 
[29]. To exclude the possibility of false positive results, we evaluated 
their acute effects on locomotor activity in the open field test (OFT) 
before conducting the FST. One hour after vehicle or saponin 
administration, each mouse was individually placed in a corner of a 
square arena (45 cm × 45 cm × 35 cm) [30] and videotaped 
continuously for 5 min. The total distance travelled was analyzed using 
the ZH-QPT Analytic System (Zhenghua, Huaibei, China).  
We also analyzed the central distance travelled in the OFT to assess 
exploration of the new environment. The apparatus was cleaned 
between tests.Decreases in the total distance travelled were 
interpreted as a decrease in locomotor activity. 
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Tail suspension test  
The mice were subjected to the TST as previously described [31]. They 
were individually suspended upside down by their tail from a ledge 
with adhesive tape (approximately 1 cm from the tip of the tail) in a 
sound-proof box, with their forelimbs 10 cm away from the tabletop. 
Each mouse was videotaped for 6 min and the cumulative time of 
immobility during the last 4 min was analyzed using the ZH-QPT 
Analytic System (Zhenghua, Huaibei, China). The mice were considered 
immobile only when they hung passively and completely motionless. 
Forced swim test  
The mice were subjected to the FST described by Porsolt [32]. Each 
mouse was placed in a glass cylinder (19 cm diameter × 25 cm height) 
with water at a depth of 18 cm (23-25 °C) for 6 min, and the 
cumulative time of immobility during the last 4 min was recorded 
using the ZH-QPT Analytic System. Immobility refers to the cessation 
of struggling and remaining motionless, with the exception of 
movements necessary to keep the mouse’s head above the water.  
Learned helplessness test  
In the learned helplessness test (LHT), the mice were exposed to 
inescapable and unpredictable electric shocks and observed for 
abnormal behaviors that reflect, to a certain extent, a deteriorated 
emotional state in humans [33]. The protocol was divided into two parts 
[34]. During the first part (helplessness induction, day 1), 60 scrambled 
randomized inescapable electric shocks (IESs; 36V, 15 s duration, 20-60 s 
intervals) were delivered through a stainless-steel grid floor in a two-
way shuttle box (BA-200, TME Technology, Chengdu, China).  
Control animals were placed in the boxes for the same period of time 
but did not receive electric shocks. During the second part 
(conditioned avoidance test, day 2), the mice were allowed to adapt to 
the shuttle box for 5 min and then were exposed to 30 avoidance trials. 
In each trial, a light signal (conditioned stimulus) was presented 
during the first 3 s, followed by a 3 s electric foot shock (36 V, 
unconditioned stimulus) that was administered via the grid floor of the 
shuttle box. A 24 s rest period than occurred. If a mouse failed to 
escape to the other compartment after the light signal (conditioned 
stimulus) and the electric foot shock (unconditioned stimulus), then an 
escape failure was recorded. 
Reserpine-induced hypothermia, palpebral ptosis, and akinesia 
The mice were randomly divided into 10 groups (n = 10 per group) 
that received saline (10 ml/kg, control group), saline (10 ml/kg, model 
group), effective fraction A (50 and 100 mg/kg), effective fraction B 
(50 and 100 mg/kg), effective fraction C (50 and 100 mg/kg), and total 
saponins D (50 and 100 mg/kg) continuously for 9 days. According to a 
previous study [35], 1 h after the final administration, the mice in the 
experimental groups (excluding the control group) were 
intraperitoneally injected with 2 mg/kg reserpine (Bangmin, 
Guangzhou, China). Three parameters (rectal temperature, degree of 
palpebral ptosis, and akinesia) were recorded 0, 1, 3, 5, and 7 h after 
reserpine treatment. The degree of palpebral ptosis was evaluated 
using the following rating scale: 0 (eyes open), 1 (eyes one-quarter 
closed), 2 (eyes half closed), 3 (eyes three-quarters closed), and 4 (eyes 
completely closed) [36]. The mice were placed in the center of a circle (7.5 
cm diameter) to measure akinesia. A mouse was judged as akinetic (i. e. 
present or not) if it stayed within the circle for more than 15 s [37]. 
5-HTP-induced head-twitch test 
The 5-HTP-induced head-twitch test [38] was performed to investigate 
the possible involvement of the serotonergic system in the 
antidepressant-like effects of Rd and Rb3. The mice were randomly 
divided into groups (n = 10 per group) and orally given distilled water, 
Rd or Rb3 (50 and 100 mg/kg), or Anafranil (30 mg/kg) for 2 days in a 
volume of 0.1 ml/10 g body weight. Thirty minutes after the last oral 
administration, each mouse was individually placed in a cage and the 
cumulative number of head twitches was counted 10-30 min 
immediately after 5-HTP injection (100 mg/kg, i. p.). 
Clonidine-induced aggressive behavior in mice 
Clonidine-induced aggression in mice [39] was assessed to determine 
the possible involvement of the noradrenergic system in the 
antidepressant-like effects of Rd and Rb3. Male mice were randomly 
divided into groups (n = 7 pairs per group) that were orally given 
distilled water, Rd and Rb3 (50 and 100 mg/kg), and maprotiline (18 
mg/kg) for 2 days in a volume of 0.1 ml/10 g body weight. Thirty 
minutes after the final administration, each animal was 
intraperitoneally injected with clonidine (50 mg/kg). Pairs of two mice 
(from the same group) were then placed together in a cage. A blind 
observer recorded biting/fighting time over 20 min. 
L-DOPA -induced running behavior in mice 
L-DOPA-induced running behavior was evaluated according to a 
previous study [40] to investigate the possible involvement of the 
dopaminergic system in the antidepressant-like effects of Rd and Rb3. 
The mice were randomly divided into groups (n = 10 per group) and 
orally given distilled water, Rd, and Rb3 (both 50 and 100 mg/kg) for 2 
days in a volume of 0.1 ml/10 g body weight. One hour after the last 
administration, the mice were intraperitoneally treated with L-DOPA 
(200 mg/kg) and then placed in the open-field box to videotape the 
distance travelled during the 20-30 min period after the injection.  
Analysis of Rb1andRb3 metabolites 
Distilled water and hydrosoluble Rb1 and Rb3 were administered to 
three groups (n = 4 per group) of KM mice that weighed 18-22 g after 
they were fasted for 24 h. Blood and brain samples were then collected 
3 h after administration. The blood samples were collected using a 
centrifugal pipe that was wetted with 3.8% sodium citrate and mixed 
equally with 100% acetonitrile before centrifugation. Brain tissues 
from each mouse were rinsed several times in normal saline (0.9%) 
and homogenized in 50% acetonitrile to prepare the homogenates. 
After centrifugation at 5000 rotations per minute for 10 min 
(Eppendorf Centrifuge 5415R, Hamburg, Germany), the supernatant 
was analyzed using an HPLC system (Shimadzu) equipped with an 
ultraviolet-visible detector. Chromatographic separation was achieved 
using an Ultimate AQ-C18 column (250 × 4.6 mm inner diameter, 5 μm 
pore size, Welch Materials Inc, Shanghai, China) at 25 °C. The isocratic 
mobile phase consisted of methanol: water (90: 10, v/v), with a flow 
rate of 0.7 ml/min. The injection volume was 20 μl, the detection wave 
length was 203 nm, and the elution time was 20 min. 
Data analysis 
All of the data were analyzed using Origin 8.0 and Microsoft Excel 2003 
software. The results are expressed as mean ± standard error of mean 
(SEM) unless stated otherwise. The statistical analysis of the results of 
reserpine-induced akinesia was performed using the χ2 test. All other 
significant differences between groups were evaluated using one-way 
analysis of variance (ANOVA) and an unpaired two-tailed Student’s t-
test. Values of p < 0.05 were considered statistically significant. 
RESULTS 
Chemical characteristics of several effective fractions from total 
saponins purified with macroporous resins 
As shown in Fig.2 fraction A mostly consisted of ppd-type ginsenosides, 
including 3.85% ginsenoside Rb1, 9.39% ginsenoside Rc, 10.77% 
notoginsenoside Fc, 2.86% ginsenoside Rb2, 20.34% ginsenoside Rb3 
and 3.25% ginsenoside Rd. Fraction B contained a large amount of 
unknown components that appeared to be gypenosides, and also a 
small amount of the above panaxadiol-type ginsenosides, including 
1.03% ginsenoside Rb1, 1.58% ginsenoside Rc, 2.16% notoginsenoside 
Fc, 0.65% ginsenoside Rb2, 4.69% ginsenoside Rb3 and 10.99% 
ginsenoside Rd. Compared with fraction A, fraction B had more 
ginsenoside Rd. Fraction C was composed of some low polar 
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ginsenosides, such as 5.88% ginsenoside Rg3, 1.76% ginsenoside C-K, 




Fig. 2: It shows HPLC chromatograms of several effective fractions 
from total saponins purified with macroporous resins 
 
 Total saponins, HPLC chromatogram of total saponins D; 50%, HPLC 
chromatogram of an effective fraction from the total saponins obtained 
from the resulting elution of a glass column wet-packed with 
macroporous resin. The column was eluted with an elution of 50% 
ethanol at an optimized flow rate of 3 BV/h. 60%, HPLC chromatogram 
of the effective fraction A obtained from the resulting elution of a glass 
column wet-packed with macroporous resin. The column was eluted 
with an elution of 60% ethanol at an optimized flow rate of 3 BV/h. 
70%, HPLC chromatogram of the effective fraction B obtained from the 
resulting elution of a glass column wet-packed with macroporous 
resin. The column was eluted with an elution of 70% ethanol at an 
optimized flow rate of 3 BV/h. 80%, HPLC chromatogram of the 
effective fraction C obtained from the resulting elution of a glass 
column wet-packed with macroporous resin. The column was eluted 
with an elution of 80% ethanol at an optimized flow rate of 3 BV/h. 
90%, HPLC chromatogram of an effective fraction from the total 
saponins obtained from the resulting elution of a glass column wet-
packed with macroporous resin. The column was eluted with an 
elution of 90% ethanol at an optimized flow rate of 3 BV/h. The 
effective fractions obtained with 60%, 70%, 80% ethanol elutions were 
referred to as effective fractions A, B, and C, respectively. 
Effects of effective fractions and total saponins on behavioral 
despair models  
The mice were randomly divided into nine groups (n =10 per group): 
control (physiological saline), effective fractions A, B, and C (50 and 
100 mg/kg), and total saponins D (50 and 100 mg/kg). The mice were 
orally administered the test drugs and vehicle for 9 days. On the 
second day, the mice were subjected to the LHT. On the third and sixth 
days, the mice were subjected to the conditioned avoidance test. On the 
fourth and seventh days, the mice were subjected to the TST. On the 
fifth and eighth days, the mice were subjected to the OFT and then the 
FST. On the ninth day, the mice were subjected to the reserpine 
reversal test. 
As shown in Fig. 3A, fraction A (50 and 100 mg/kg) reduced the 
number of escape failures by 24.4% and 28%, respectively, on the 
third day and 30.4% and 32.8% on the sixth day (ANOVA and t-test; 
p<0.01, vs. control). Total saponins D (50 and 100 mg/kg) exerted 
similar effects as fraction A. Fractions B and C (100 mg/kg) both 
significantly decreased the number of escape failures on the third day 
(t-test; both p<0.01, vs. control) and sixth day (ANOVA and t-test; both 
p<0.01, vs. control). Fraction C (50 mg/kg) had no significant effect 
compared with the control group. Fraction B (50 mg/kg) exerted a 
significant effect on the third day (t-test; p<0.05, vs. control) and sixth 
day (ANOVA and t-test; p<0.01, vs. control). 
The TST results (Fig. 3B) are expressed as a percentage of the mean 
immobility time in the control group. On the fourth and seventh days, 
fraction C (100 mg/kg) significantly reduced immobility time by 29.3% 
and 24% (t-test; p<0.05, vs. control), respectively. The other groups did 
not exhibit significant decreases compared with the control group. 
The effects of effective fractions A, B, and C and total saponins D on the 
total distance travelled in the OFT are shown in Fig. 3C. On day 5, total 
saponins D (50 mg/kg) significantly decreased the total distance 
travelled (t-test; p<0.05, vs. control), but the other groups did not 
exhibit significant differences. On day 8, none of the groups exhibited 
significant differences compared with the control group. The effects of 
fractions A, B, and C and total saponins D on the central distance 
travelled in the OFT are shown in Fig. 3E. On day 5, no significant 
differences were observed among groups. On day 8, fraction C (50 
mg/kg) significantly decreased the central distance travelled by 44.4%. 
The FST results are shown in Fig. 3D. On the fifth day, fractions A (100 
mg/kg) and C (100 mg/kg) significantly reduced immobility time by 
27.8% (ANOVA and t-test; p<0.01, vs. control) and 14.6% (t-test; 
p<0.05, vs. control). The other groups did not exhibit significant 
differences. On the eighth day, fractions A (50 mg/kg) and D (100 
mg/kg) significantly decreased immobility time by 15.3% (t-test; 
p<0.05, vs. control) and 24.8% (t-test; p<0.01, vs. control), respectively. 
The other groups did not exhibit significant differences. 
Summarizing the above results, three effective fractions from SCLPN 
presented more significant effects in the LHT than in the TST and FST. 
Fraction A at both dosages exerted significant effects in the LHT and 
FST on both test days. Fraction B exerted significant effects only in the 
LHT. Fraction C at only 100 mg/kg exerted significant effects in the 
LHT, TST, and FST. In summary, fractions A and C presented more 
robust antidepressant potential than fraction B, and fraction C 
significantly influenced the central distance travelled in the OFT. 
Effects of effective fractions on reserpine-induced syndrome 
Reserpine is an antihypertensive drug that depletes neuronal storage 
granules of biogenic amines in the brains of rodents and produces a 
clinically significant depressive-like state [41]. Mice will show several 
symptoms such as, eyelid drooping, hypothermia, and akinesia, in 
response to reserpine.  
Fig. 4A shows a significant reduction of rectal temperature from the 3rd 
hour to the 7th hour after reserpine administration. With the exception 
of the group that received the fraction A at 50 mg/kg at the 1st hour, 
pretreatment with fraction A significantly attenuated the hypothermic 
response from the 1st hour to the 7th hour (t-test; p< 0.01, vs. model). 
Fraction C at both dosages significantly increased rectal temperature 
from the 1st hour to the 7th hour (t-test, at the 1st hour, p < 0.05, vs. 
model; at the 3rd, 5th, and 7th hours, p < 0.01, vs. model). With the 
exception of the group that received total saponins D at 100 mg/kg at 
the 1st hour, pretreatment with total saponins D significantly increased 
rectal temperature from the 1st hour to the 7th hour. Neither fraction B 
group exhibited a significant increase in rectal temperature during the 
entire trial.  
The degree of palpebral ptosis in mice (Fig. 4B) was significantly 
aggravated by reserpine treatment compared with controls. Fraction A 
(100 mg/kg) significantly reversed palpebral ptosis from the 1st hour 
to the 7th hour compared with the model group. However, fraction A 
(50 mg/kg) significantly ameliorated palpebral ptosis only at the 1st 
and 7th hours (t-test; p < 0.05, vs. model). A similar effect was observed 
with fraction D (50 mg/kg). The degree of palpebral ptosis in the 
fraction B groups was significantly decreased only at the 1sthour (t-
test; p < 0.05, vs. model). Compared with the model group, total 
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reduced in the degree of palpebral ptosis at the 1st, 3rd, and 7th hours. 
Fraction C (100 mg/kg) significantly attenuated the degree of 
palpebral ptosis only at the 7th hour (t-test; p < 0.01, vs. model). In the 
control group, all of the mice opened their eyes completely in the test (data 
from the control group were all zero and are not presented in the figure). 
The χ2 test was used to analyze the results of the akinesia test. As 
shown in Fig. 4C, the model group exhibited a significant reduction of 
the number episodes of creeping outside thecircle from the 1st hour to 
the 7th hour compared with the control group (p < 0.01). Fraction A, B, 
and C and total saponins D did not exert significant effects compared 
with the model group at the 1st, 3rd, 5th, and 7th hours. The results were 
standardized and are presented as a ratio of episode of creeping 
outside the circle. With the exception of fraction B (50 mg/kg) and 
fraction D (100 mg/kg), all of the other groups presented an increase 
in the ratio of the number of episodes of creeping outside the circle 
compared with the model group. 
 
 
Fig. 3: It shows effects of fractions A, B, and C and total saponins D in behavioral despair models 
 
The fig. shows the effects of fractions A, B, and C and total saponins D on (A) escape failures in the LHT (B), immobility time relative to controls in the 
TST (C), total distance travelled in the OFT (D), immobility time in the FST, *p<0.05, **p<0.01, vs. control group (t-test). #p<0.05, ##p<0.01, vs. control 
group (ANOVA). LHT, learned helplessness test; TST, tail suspension test; OFT, open field test; FST, forced swim test; Control, physiological saline; A-low, 
50 mg/kg fraction A, A-high, 100 mg/kg fraction A; B-low, 50 mg/kg fraction B; B-high, 100 mg/kg fraction B; C-low, 50 mg/kg fraction C; C-high, 100 
mg/kg fraction C; D-low, 50 mg/kg total saponins D; D-high, 100 mg/kg fraction D. 
 
In summary, fractions A and C and total saponins D improved 
reserpine-induced hypothermia. Fraction B did not significantly 
influence this parameter. Fraction A had a similar effect on reserpine-
induced eyelid drooping and akinesia as fraction C, and fraction B 
exerted weaker action in both tests.  
Effects of Rd, Rb1, R1, and Rg1 in behavioral despair models  
The three 20(S)- ppd-type ginsenosides Rd, Rb1, and Rb3, the main 
constituents of SCLPN [42], were distributed into effective fractions 
that were purified with macroporous resin, specially fraction A. 
Notoginsenoside R1 is characteristic of PN [43], and ginsenoside Rg1 is 
a 20(S)- ppd-type saponin. We chose R1 and Rg1 to investigate 
whether these types of saponins are responsible for the antidepressant 
effects of SCLPN. The antidepressant effect of Rb3, a major component 
of SCLPN, has been previously explored by our group. Therefore, we 
mainly evaluated the antidepressant effects of four representative 
saponin monomers (Rd, Rb1, R1, and Rg1). 
The mice were randomly divided into 11 groups (n = 10 per group) 
that were orally administered with physiological saline (control), Rd, 
Rb1, R1 and Rg1 (50, 100 mg/kg), paroxetine (6 mg/kg), and 
maprotiline (18 mg/kg) for 6 days. The mice were subjected to the TST 
on the third day and OFT (with the exception of the paroxetine and 
maprotiline groups) and then the FST on the next day. On the fifth day, 
the mice were subjected to the LHT，followed by the conditioned 
avoidance test the next day.  
In the TST (Fig. 5A), both the 50 and 100 mg/kg Rd and R1 groups 
exhibited a significant decrease in immobility time compared with the 
control group (ANOVA and t-test). The 50 mg/kg Rb1 group exhibited 
a significant decrease in immobility time (t-test; p < 0.05, vs. control). 
Rg1 at both 50 and 100 mg/kg had no significant effects on immobility 
time. The positive control drugs paroxetine and maprotiline 
significantly decreased immobility time by 22.2% and 10%, 
respectively (ANOVA: paroxetine, p < 0.01, maprotiline, p < 0.05, vs. 
control; t-test: both p < 0.01 vs. control). 
As shown in Fig. 5B, both paroxetine and maprotiline exerted 
significant effects in the FST compared with the control group (ANOVA 
and t-test, p < 0.01), reducing immobility time by 20.0 % and 18.8%, 
respectively. Rd at both 50 and 100 mg/kg had similar effects as 
paroxetine and maprotiline in the FST, decreasing immobility time by 
22.6% and 21.6%, respectively. Rg1 at 50 and 100 mg/kg significantly 
decreased immobility time (ANOVA: 100 mg/kg Rg1, p < 0.01, 50 
mg/kg Rg1, p < 0.05, vs. control; t-test: both p < 0.01, vs. control). The 
50 mg/kg R1 and Rb1 groups exhibited a significant decrease in 
immobility time in the FST (ANOVA and t-test; p < 0.01, vs. control), but 
the 100 mg/kg R1 and Rb1 groups did not exhibit significant 
differences from the control group. 
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Fig. 4: It shows effects of effective fractions A, B, and C and total saponins D on reserpine-induced hypothermia, palpebral ptosis, and akinesia. 
(A) Rectal temperature (B) Degree of palpebral ptosis (C) Number of episodes of creeping outside the circle. No significant difference was 
found among groups (χ2test). *p<0.05, **p<0.01, vs. control group (t-test). Control, noreserpine + saline; Model, reserpine + saline; A-l, 
reserpine + 50 mg/kg effective fraction A; A-h, reserpine + 100 mg/kg effective fraction A; B-l, reserpine + 50 mg/kg effective fraction B; B-h, 
reserpine + 100 mg/kg effective fraction B; C-l, reserpine + 50 mg/kg effective fraction C; C-h, reserpine + 100 mg/kg effective fraction C; D-l, 
reserpine + 50 mg/kg total saponins D; D-h, reserpine + 100 mg/kg effective fraction D. 
 
The Rd (50 mg/kg) and Rg1 (50 and 100 mg/kg) groups exhibited a 
significant increase in the total distance travelled (Fig. 5C) in the OFT 
compared with controls (t-test; p < 0.05), indicating that Rd and Rg1 
may enhance central nervous system excitation. The Rd (50 mg/kg) 
group exhibited a significant increase in the central distance travelled 
(Fig. 5D) in the OFT, whereas the 50 mg/kg Rg1 group exhibited a 
significant reduction of central locomotion compared with the control 
group (t-test; Rd, p < 0.01, Rg1, p < 0.05).  
In the LHT (Fig. 5E), Rd (50 and 100 mg/kg) reduced the number of 
escape failures by 27.7% and 19.2%, respectively (ANOVA and t-test; p 
< 0.01, vs. control). Rb1 and Rg1 similarly significantly decreased the 
number of escape failures in the LHT by 31.1% (50 mg/kg Rb1), 38.6% 
(100 mg/kg Rb1), and by 16.1% (50 mg/kg Rg1), 25.5% (100 mg/kg 
Rg1). The R1 groups did not exhibit significant differences compared 
with the control group. 
Based on the results of the TST, FST, OFT, and LHT, among the four 
saponin monomers, Rb1 and Rd exerted apparent effects in the TST, 
FST and LHT. R1 exerted apparent effects in the TST and FST, and Rg1 
exerted effects in the FST and LHT. Rd and Rg1 also induced distinct 
changes in the OFT. Rd and Rb3 presented the most significant effects 
and were subsequently chosen to explore mechanisms of action that 
involve monoamine neurotransmitters in behavioral models. 
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Fig. 5: It shows effects of Rd, Rb1, R1, and Rg1 in behavioral despair models. The fig. shows the effects of ginsenoside Rd, Rb1, R1, and Rg1 and 
notoginsenoside R1 on (A) immobility time in the TST, (B) immobility time in the FST, (C) total distance travelled in the OFT, (D) central 
distance travelled in the OFT, and (E) escape failures in the LHT. *p<0.05, **p<0.01, vs. control group (t-test). #p<0.05, ##p<0.01, vs. control group 
(ANOVA). OFT, open field test; FST, forced swim test; TST, tail suspension test; LHT, learned helplessness test. 
 
Mechanisms of action of Rb3 and Rd involving monoamine 
neurotransmitters in three behavioral models  
To further investigate the possible involvement of specific monoamine 
neurotransmitters in the antidepressant-like effects of Rd and Rb3, 
three animal models were established to test whether Rd and Rb3 
affect 5-HT, NE, and DA. Some clinical antidepressants can increase the 
concentration of 5-HT in the synaptic cleft by blocking its reuptake to 
produce antidepressant-like effects [44, 45].  
5-Hydroxytryptophan can be converted to 5-HT, a neurotransmitter 
that can enhance head-twitch behavior in mice. Therefore, the 5-HTP-
induced head-twitch test was used to examine whether a drug can 
increase 5-HT levels. Rb3 (50 and 100 mg/kg) and Rd (100 mg/kg) 
significantly increased in the number of head twitches (ANOVA and t-
test; p < 0.01), similar to the positive control drug anafranil (Fig. 6A), 
indicating that Rb3 and Rd may enhance 5-HT levels in vivo.  
A previous study found that clonidine induced fighting behavior in 
mice at a high concentration [46]. This kind of behavior was 
suppressed by a noradrenergic receptor agonist. As shown in Fig. 6B, 
pretreatment with Rb3 (50 and 100 mg/kg) and Rd (100 mg/kg) 
significantly decreased the number of episodes of fighting behavior 
induced by clonidine compared with the control group (ANOVA and t-
test; p < 0.01), demonstrating that Rb3 and Rd enhanced NE release 
similarly to maprotiline.  
 L-DOPA can induce running behavior in mice by activating 
dopaminergic systems [47]. Running behavior induced by L-DOPA is 
promoted by selective dopaminergic receptor agonists, indicating 
whether a drug activates dopaminergic neurons. In the present study, 
mice treated with Rb3 (50 and 100 mg/kg) and Rd (100 mg/kg) 
exhibited a significant enhancement of running velocity compared with 
the control group (ANOVA and t-test; p < 0.01; Fig. 6C). These results 
suggest that the effects of Rb3 and Rd might involve functional 
stimulation of dopaminergic pathways. Rb3 and Rd exerted obvious 
effects in three behavioral models, and the effects appeared to involve 
5-HT, NE, and DA. However, the 50 mg/kg Rd group did not exhibit 
significant differences in the three experiments compared with the 
control group. 
 
Fig. 6: It shows the effects of Rd and Rb3 in three behavioral 
models appear to involving monoamine neurotransmitters. (A) 
Effects of Rd and Rb3 on the number 5-HTP-induced head 
twitches in mice. (B) Effects of Rd and Rb3 on clonidine-induced 
aggressive behavior (episodes of fighting) in mice. (C) Effects of 
Rd and Rb3 on L-DOPA-induced running behavior (running 
velocity) in mice. *p<0.05, **p<0.01, vs. control group (t-test). 
#p<0.05, ##p<0.01, vs. control group (ANOVA). Control distilled 
water; Rd-low, 50 mg/kg Rd; Rd-high, 100 mg/kg Rd; Rb3-low, 50 
mg/kg Rb3; Rb3-high, 100 mg/kg Rb3; mapro, maprotiline. 
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Metabolites of Rb1 and Rb3 in mouse blood and brain  
Numerous studies have shown that a range of metabolites of 
ginsenosides might be formed in the gastrointestinal tract and might 
be the active principles in the body. Ginsenoside Rb1 is metabolized to 
secondary saponins and sapogenin or its corresponding oxygenated 
metabolites through the following pathway: Rb1 → Rd → F2, Rg3 → 
Compound K (CK), Rh2 →20 (S)-protopanaxadiol aglycon [48, 49]. 
Blood and brain samples underwent HPLC detection 3h after oral 
administration of Rb1 and Rb3 at a dosage of 500 mg/kg. The HPLC 
chromatograms (Fig. 7) showed that ginsenoside Rh2, C-K and 20(S)-
PDSs were mainly detected in blood samples from mice that received 
Rb1 and Rb3. Only PDS were detected in the brain samples. These 
results are consistent with previous studies. However, other 
metabolites of Rb1 and Rb3 in blood and brain remain unknown and 
require further investigation. 
 
Fig. 7: It shows HPLC chromatograms of metabolites in mouse 
blood and brain samples collected 3h after oral administration of 
distilled water, Rb1, and Rb3. CBL, HPLC chromatogram of 
metabolites in blood from the control group in the pre-test; DBL, 
HPLC chromatogram of metabolites in blood in the Rb3 group in 
the pre-test; Blood (control, Rb1, Rb3), HPLC chromatograms of 
metabolites in mice blood samples collected 3h after oral 
administration of distilled water, Rb1, and Rb3, respectively, in 
the final experiment; Brain (control, Rb1, Rb3), HPLC 
chromatograms of metabolites in mouse brain samples collected 
3h after oral administration of distilled water, Rb1, and Rb3, 
respectively, in the final experiment; C-K and Rh2, HPLC 
chromatogram of the ginsenoside C-K and Rh2 standard; 20 (S)-
protopanaxadiol saponins, HPLC chromatogram of the 20 (S)-
protopanaxadiol saponins standard. 
 
DISCUSSION 
Macroporous resins are effective and economical for the 
separation and purification of ppd-type ginsenosides from total 
saponins 
In recent years, macroporous resins have been widely used to separate 
and purify the bioactive constituents of herbs because of their 
relatively lower cost and time, higher efficiency, and less labor 
intensiveness compared with other routine methods [50]. 
Furthermore, macroporous resins easily regenerate and endure 
hydrophilic polymers because of their high adsorption ability [51]. The 
macroporous resign method is based on differences in the molecular 
polarity, weight, and shape of various molecules in the solution, 
resulting in different affinities for the adsorbent [52]. 
Some methods have been used to separate two types of saponins (PTSs 
and PDSs) in pharmacological research, such as liquid-liquid 
extraction, silica gel column chromatography, dialysis, and 
precipitation with sodium hydrate, but subsequent studies have shown 
that macroporous resins are a more favorable for separating ppd-type 
ginsenosides from total saponins [50, 53]. 
Based on these merits, we used macroporous resins to separate and 
purify SCLPN into five fractions with different characteristics Fig.2 We 
found different distributions of gensinoside compounds in three (A, B, 
C) of the five fractions. However, the three effective fractions (A, B, C) 
also exerted distinct antidepressant effects in several modes of 
depressive behavior in mice. This demonstrates that macroporous 
resin purification can be used to produce effective fractions from 
SCLPN with stronger antidepressant effects. The precise experimental 
conditions of macroporous resins still remain to be explored to 
improve the high-purity production of components from SCLPN. 
Protopanaxadiol-type ginsenosides may be the main component 
of SCLPN that contributes to antidepressant effects.  
San-Chi, the roots of Panax notoginsenoside Radix (Burk) F. H. Chen, 
has been commonly used in traditional Chinese medicine for 
thousands of years. Modern chromatographic methods have shown 
that it is rich in saponins in the aerial parts (leaf and flower) of P. 
notoginseng, similar to the underground parts (root, fiber root, 
rhizome) [22]. More than 60 dammarane saponins have been isolated 
from the roots, rhizome, rootlets, fibers, leaves, flower buds, seeds, and 
fruit pedicels of Notoginseng. Most of these saponins are ginsenosides 
and notoginsenosides [54], which can be classified according to their 
structures as 20(S)-PTSs and 20(S)-PDSs. PTSs and PDSs are the major 
constituents and are equally present in the roots of Panax notoginseng, 
and Panax notoginsenoside R1, and ginsenosides Rg1, Rd, Re, and Rb1 
are considered to be the principal active components. The leafs and 
flowers containe ppd-type saponins only and are rich in ginsenoside 
Rc, Rb2 and Rb3, which are rare in the underground parts of Panax 
notoginseng [22, 50]. Other types of sapogenins were also isolated 
from the leaves of P. notoginseng, including quercetin 
galactopyranoside [55]. Although we did not identify every peak of 
SCLPN, three effective fractions (A, B, C) could be obtained through 
macroporous resin isolation and purification. According to our analysis 
and other reports, fraction A mainly consisted of ppd-type 
ginsenosides. Fraction B contained a small amount of ppd-type 
ginsenosides, and its major component is unknown. Fraction C 
comprised low-polar ppd-type ginsenosides that could be various 
deglycosylated metabolites. The evaluation of antidepressant-like 
effects showed that fractions A and C had more antidepressant effects 
than fraction B. Thus, ppd-type ginsenosides may be the major 
components of SCLPN that contribute to its antidepressant effects.  
Ginsenosides have been shown to stimulate brain function and 
produce numbers of beneficial effects to protect against various 
diseases. The actions of ginsenosides have been attributed to specific 
pharmacological effects on particular central nervous system targets 
[56]. Through effects on neurotransmitter systems, ginsenosides may 
enhance brain function, particularly cognition and emotion. 
Monoamine neurotransmitters (e. g., 5-HT, NE, and DA) in the central 
nervous system have been suggested to play a vital role in the 
pathogenesis of depression [57]. The ginseng fraction has been 
reported to mainly include ginsenoside Rd, which concentration-
dependently reduced the uptake of γ-aminobutyric acid, NE, DA, 
glutamate, and 5-HT, similar to ginsenoside Rc [58]. Ginsenosides 
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increased DA and NE levels in the cerebral cortex in rodents [10, 59]. 
Ginsenosides Rg1 and Rb1 were shown to play a major role in the 
modulation of neurotransmission, which Rb1 promoted 
neurotransmitter release by increasing the phosphorylation of 
synapsins via the protein kinase A pathway, whereas Rg1 did not affect 
the phosphorylation of synapsins [60]. thses results suggest that the 
effect of ginsenoside Rg1 involves PTSs, in contrast to the effect of 
ginsenoside Rb1, which involves PDSs [61]. Consistent with the above 
reports, our previous data indicated that SCLPN exerted its 
antidepressant-like effect by increasing the levels of 5-HT, DA, and NE 
[27]. Furthermore, effective fraction A purified from SCLPN 
ameliorated hypothermia, ptosis, and akinesia induced by reserpine in 
mice, indicating that the fraction A exerted its antidepressant-like 
effect by restoring brain monoamine neurotransmitter levels. 
Moreover, these ppd-type saponin monomers (e.g., Rb3) might 
produce their antidepressant effects by selectively blocking 5-HT and 
NE reuptake [28]. Rb3 and Rd altered several behavioral parameters, 
including 5-HTP-induced head twitches, clonidine-induced aggression, 
and L-DOPA-induced running, in mice. Therefore, ppd-type 
ginsenosides may be the main component of SCLPN that contributes to 
its antidepressant effects and exerts these effects through 
neurotransmitter modulation via multiple pathways.  
Differental effects of ginsenoside attributable to different 
chemical structures and bioavailability 
Ginsenoside may have different pharmacological and mechanisms 
because of their different chemical structures. The complexity of the 
efficiency of ginsenosides is further increased because of the 
biotransformations that are elicited by low gastric pH, the presence of 
digestive enzymes, and microorganisms that form intestinal flora [62]. 
Protopanaxadiol sapoins possess sugar moieties at the C-3 and/or C-20 
positions, whereas the PTSs have a hydroxyl group at C-3 and sugar 
moieties at C-6 and/or C-20. The bioconversion of ginsenosides occurs 
mainly in the large intestine through bacterial action, and intestinal 
bacteria cleave oligosaccharide chains that are connected to C-3, C-6, 
or C-20 hydroxyl groups stepwise from the terminal sugar. The sugar 
on C-20 was more easily eliminated under acidic conditions than 
sugars found at other positions. The bioconversion of ginsenosides by 
the intestinal microbiota is mainly based on the deglycosylation at the 
C3 position [63]. A bioconversion route of the ppd ginsenosides has 
been proposed, in which ppd ginsenosides (Rb1,Rc, Rb2, Rd) are 
metabolized by intestinal bacteria to compound K via ginsenosides Rd 
and F2 to reach the systemic circulation [63, 64]. Intact undecomposed 
G-Rb1 is absorbed and remain as detectable in plasma for 3 h prior to 
excretion after 6 h [63]. After oral administration of a Sanqi 
ginsenoside powder in rats, Panax notoginsenoside R1, and 
ginsenosides Rg1, Rd, Re, and Rb1 rapidly reached peak concentrations 
in plasma within approximately 0.75 h, hinting at their rapid 
absorption [65]. Poor membrane permeability and rapid extensive 
active biliary excretion are two primary factors that limit systemic 
exposure to most Sanqi ginsenosides and their deglycosylated 
metabolites. Many reports proved that PDS monomers (Ra3, Rb1, Rc, Rd, 
and so on) or their serial deglycosylated products (F2, CK, and so on) are 
measurable in rat plasma, even in the central nervous system [21]. 
Collectively, the effects of ginsenosides could be attributable to intact 
undecomposed molecules and serial degradation metabolites that reach 
the tissues. The different degradation routes and pharmacokinetics profiles 
of each ginsenoside could lead to different impacts on the same disease or 
physiological function,demonstrating why fractions A and C, and different 
ginsenoside monomers have different effects. 
These ginsenosides may have potential antidepressant-like actions 
because of the structures of these compounds. These dammarane-type 
tetracyclic triterpenoid saponins are similar to the TCA antidepressant 
desipramine molecule. Both consist of multi-rings and a methyl 
aminopropyl chain (Fig.1). Researchers have determined the crystal 
structure of desipramine in complex with the bacterial leucine 
transporter, a homolog of the 5-HT transporter, NE transporter, and 
DA transporter, revealing how TCAs and SSRIs block neurotransmitter 
reuptake [66]. The desipramine molecule binds at the inner end of the 
extracellular cavity of the transporter with its three rings tilted at a 40° 
angle to the membrane plane. The methyl aminopropyl chain projects 
toward the extracellular space, and is held in place by a hairpin loop 
and salt bridge. This binding site is separated from the leucine-binding 
site by the extracellular gate of the transporter to block substrate 
transport. Similarly, it is possible that dammarane-type tetracyclic 
triterpenoid saponins also block neurotransmitter reuptake by 
noncompetitively blocking the substrate binding with the transporter, 
similar to desipramine. In addition to different pharmacokinetics 
profiles, ginsenosides or their metabolites may exert differential effects 
on neurotransmitter reuptake because of variations in their chemical 
structures, hydroxyl groups, and the stereoselectivity of ginsenosides 
have been reported to be related to the cancer chemopreventive effect of 
American ginseng [67]. The polar hydroxyl group at C-3 may influence 
the transmembrane action of ppd-type ginsenosides [68]. The sugar 
moieties at C-6 increase the steric hindrance of these molecules to target 
proteins, confirmed by molecular modeling and docking [69]. The sugar 
molecules，hydroxyl groups, and stereoselectivity of ginsenosides might 
also be involved in its actions on central nervous system targets, which 
should be further investigated.  
CONCLUSION 
The present study confirmed the antidepressant-like effects of 
components (three effective fractions and five saponin monomers) of 
SCLPN in behavioral models in mice. Protopanaxadiol saponins of 
SCLPN may be the main components that contribute 
to its antidepressant effects. We also found that these saponin 
monomers may exert these effects through monoamine 
neurotransmitter mechanism. The present study lays the theoretical 
foundation for the possible industrial production of effective fractions 
of SCLPN using macroporous resins and development of effective and 
safe antidepressant medications. 
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